Research progress of peripheral T-cell lymphoma: reports from the 57th American Society of Hematology annual meeting

Abstract

Peripheral T-cell lymphoma (PTCL) accounting for 10% to 15% of non-Hodgkin lymphoma (NHL) is characterized highly heterogeneous and aggressive clinical course. PTCL patients are prone to suffer from chemotherapy refractory and disease progression. Reports on research progress of PTCL in the 57th American Society of Hematology annual meeting covered multiple respects of PTCL. In basic research, the novel partner genes further improve the pathogenesis mechanism of ALK+ anaplastic large cell lymphoma (ALCL). For prognostic indicators, GATA-3 expression detected by immunochemical assay provide a novel tool to monitor PTCL prognosis. Belinostat-CHOP, brentuximab vedotin-CHP, romidepsin-ICE regimens and stem cell transplantation provide more options for patients with PTCL, and the novel drugs such as alisertib, darinaparsin and denileukin diftitox offer new hope for PTCL patients in preclinical trials. Key words: Lymphoma, T-cell, peripheral; Diagnosis; American Society of Hematology annual meeting